SGK
IMNM icon

Steigerwald Gordon & Koch’s Immunome IMNM Stock Holding History

Steigerwald Gordon & Koch’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-200
Closed -$4.3K – 837
2025
Q4 		$4.3K Hold
200
– – ﹤0.01% 707
2025
Q3 		$2.34K Buy
+200
New +$1.99K ﹤0.01% 714

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Steigerwald Gordon & Koch's IMNM Position: Q1 2026 in Review

Steigerwald Gordon & Koch sold out of Immunome (IMNM) in Q1 2026, closing a stake of 200 shares — an estimated $4.3K sold.

Steigerwald Gordon & Koch first reported a position in IMNM in Q3 2025 and held it in 2 quarters. The position peaked at $4.3K in Q4 2025. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Steigerwald Gordon & Koch reported no remaining Immunome position as of Q1 2026 after selling out during the quarter.
  • Steigerwald Gordon & Koch sold 200 Immunome shares in Q1 2026, an estimated $4.3K.
  • Steigerwald Gordon & Koch first reported a position in Immunome in Q3 2025 and held it in 2 quarters.
  • Steigerwald Gordon & Koch's Immunome position peaked at $4.3K in Q4 2025.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Steigerwald Gordon & Koch's 13F filing for Q1 2026, filed 28 Apr 2026.